753 related articles for article (PubMed ID: 2521527)
1. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
Gunn TR; Bosley A; Woodfield DG
N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study.
Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH
Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children.
Moyes C; Milne A
N Z Med J; 1988 Apr; 101(843):162-4. PubMed ID: 2965799
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
[TBL] [Abstract][Full Text] [Related]
7. Immune response to hepatitis B vaccine in premature neonates.
Chawareewong S; Jirapongsa A; Lokaphadhana K
Southeast Asian J Trop Med Public Health; 1991 Mar; 22(1):39-40. PubMed ID: 1835140
[TBL] [Abstract][Full Text] [Related]
8. A randomized double-blind clinical trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine compared with a plasma-derived vaccine.
Halliday ML; Rankin JG; Bristow NJ; Coates RA; Corey PN; Strickler AC
Arch Intern Med; 1990 Jun; 150(6):1195-200. PubMed ID: 2141247
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of hepatitis B in children in a high risk New Zealand community, and control using recombinant DNA vaccine.
Milne A; Heydon JL; Hindle RC; Pearce NE
N Z Med J; 1989 Apr; 102(866):182-4. PubMed ID: 2523525
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a recombinant DNA hepatitis B vaccine in neonates.
Meheus A; Alisjahbana A; Vranckx R; Sukadi A; Usman A; Ngantung W; Sugita E; Safary A; André F; Reniers J
Postgrad Med J; 1987; 63 Suppl 2():139-41. PubMed ID: 3317350
[TBL] [Abstract][Full Text] [Related]
11. [Reactivity and immunogenicity of Engerix B, the recombinant DNA vaccine against hepatitis B].
Borcić B; Gasparović V; Mihaljevic I; Aleraj B; Margan IG
Acta Med Iugosl; 1989; 43(4):247-54. PubMed ID: 2534021
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults.
Crovari P; Crovari PC; Petrilli RC; Icardi GC; Bonanni P
Postgrad Med J; 1987; 63 Suppl 2():161-4. PubMed ID: 3317356
[TBL] [Abstract][Full Text] [Related]
13. Vaccination against hepatitis B virus infection in neonates.
Pongpipat D; Suvatte V; Assateerawatts A
Helv Paediatr Acta; 1984 Aug; 39(3):231-6. PubMed ID: 6242403
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of yeast-derived hepatitis B vaccines in young adults.
Bergamini F; Zanetti A
Postgrad Med J; 1987; 63 Suppl 2():137-8. PubMed ID: 3317349
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of Engerix-B in healthy Malaysian medical students.
Isahak I; Abdul Malik Y; Hakim AS; Baharin R
Singapore Med J; 1990 Aug; 31(4):314-6. PubMed ID: 2147781
[TBL] [Abstract][Full Text] [Related]
17. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
Schiff GM; Sherwood JR; Zeldis JB; Krause DS
J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, reactogenicity and comparison of two doses of recombinant DNA yeast-derived hepatitis B vaccine in Ethiopian children.
Tsega E; Tafesse B; Horton J; Nordenfelt E; Wolde-Hawariat G; Hansson BG; Lindberg J
Trop Geogr Med; 1991; 43(1-2):220-7. PubMed ID: 1836290
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigen.
Frazer IH; Jones B; Dimitrakakis M; Mackay IR
Med J Aust; 1987 Mar; 146(5):242-5. PubMed ID: 2950303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
